Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access Study

Prospective Observational Evaluation of Procurement Reliability, Distribution Restrictions, Supply-Chain Disruptions, and Clinical Access to Intracardiac Echocardiography Catheters

The ICE-ACCESS study is a prospective observational study designed to evaluate how procurement reliability, distribution restrictions, supply-chain interruptions, and device availability affect access to intracardiac echocardiography (ICE) catheters and related clinical care. The study will document real-world procurement attempts, fulfillment outcomes, order delays, cancellations, product substitutions, distributor restrictions, acquisition timelines, and other supply-access events involving ICE catheter devices.

Where participant-level clinical data are available under the approved protocol, the study will also examine whether device-access problems are associated with procedure delays, rescheduling, changes in planned device use, alternative sourcing, increased administrative burden, or other measurable effects on care delivery.

The study does not assign participants to a device or treatment and does not alter clinical decision-making. Procurement and clinical events are observed as they occur in routine practice. The study is intended to develop a structured evidence base for understanding the reliability of the medical-device supply chain and the potential relationship between procurement disruption and timely access to cardiovascular procedures.

Intracardiac echocardiography catheters are specialized medical devices used to provide real-time intracardiac imaging during selected electrophysiology, structural heart, and other cardiovascular procedures. Timely access to these devices may depend on a network of manufacturers, reprocessors, distributors, purchasing organizations, healthcare facilities, logistics providers, and other supply-chain participants.

ICE-ACCESS is designed to systematically characterize real-world access to intracardiac echocardiography catheters by recording procurement and fulfillment events over the study period. The protocol focuses on objectively measurable events rather than presuming that any supplier, manufacturer, distributor, or other organization is responsible for a particular outcome.

Study observations may include:

Date and time of an initial procurement request. Device manufacturer, model, catalog number, size, configuration, and regulatory status when available.

Quantity requested. Supplier or distributor contacted. Quotation availability and quotation response time. Representations regarding inventory or product availability. Account-eligibility or purchasing restrictions communicated to the purchaser. Order acceptance or rejection. Order confirmation and subsequent cancellation. Allocation or back-order status. Estimated and actual fulfillment dates. Shipping and logistics delays. Changes in purchase price or acquisition terms. Requests for purchaser qualification or supporting documentation. Product substitutions or alternative device sourcing. Number of sourcing attempts required to obtain the requested device. Administrative time required to resolve an access issue. Final procurement disposition.

The study may compare procurement events according to device type, supplier category, manufacturer, reprocessed versus original-manufacturer product status, acquisition channel, geographic region, purchasing pathway, or other predefined supply-chain characteristics.

For participants whose clinical pathway is associated with a documented device-access event, protocol-authorized data may be used to evaluate health-system or procedural consequences. These observations may include the interval between planned and actual procedures, procedure rescheduling, postponement, cancellation, use of an alternative device, changes in procedure planning, additional sourcing requirements, and other predefined measures of clinical-access disruption.

The protocol does not require the treating clinician to select a particular ICE catheter. Clinical decisions remain under the control of the treating healthcare professionals and are not dictated by the study. The study does not experimentally withhold a device, create an artificial shortage, intentionally delay a procedure, or direct suppliers to deny or restrict access.

A central objective is to distinguish among different categories of supply-chain events, including routine inventory limitations, logistical delays, commercial purchasing restrictions, account-qualification requirements, manufacturer or distributor allocation policies, order-processing failures, cancellations, product discontinuation, and other documented reasons for non-fulfillment.

Source documentation may include purchase requests, purchase orders, quotations, invoices, supplier correspondence, distributor communications, order confirmations, cancellation notices, shipping records, catalog information, product identifiers, device availability records, and other contemporaneous procurement documentation. When permitted under the protocol, relevant clinical scheduling or procedural records may also be reviewed to establish the timing and consequence of a documented access event.

Each event may be assigned a standardized study identifier and chronology so that the sequence from initial device request through final disposition can be reconstructed. Electronic integrity controls, including document hashing, serialized event identifiers, audit trails, and controlled versioning, may be used to preserve the provenance of research records. These controls are intended to support research data integrity and do not independently establish legal liability or regulatory noncompliance.

Potential study endpoints include successful procurement rate, time to confirmed fulfillment, time to delivery, cancellation rate, restriction rate, substitution rate, number of sourcing attempts, acquisition-price variability, administrative burden, and the frequency and duration of associated procedure delays.

Exploratory analyses may assess whether particular procurement characteristics are associated with increased time to fulfillment or a higher probability of an access disruption. Analyses may also evaluate patterns of repeated non-fulfillment, variation among supply channels, and differences between represented product availability and documented procurement outcomes.

The study is observational and is intended to characterize medical-device access and supply-chain reliability using systematically collected data. Findings may inform healthcare procurement practices, supply-chain resilience strategies, quality-improvement activities, future clinical-access research, and evaluation of medical-device availability without predetermining the conduct or liability of any particular organization.

Inclusion Criteria:

• Age 18 years or older.
• Participant is scheduled for, referred for, or undergoing an electrophysiology, cardiac ablation, structural heart, or other cardiovascular procedure for which intracardiac echocardiography or an ICE catheter is clinically planned, requested, considered, or utilized.
• A documented ICE-catheter procurement or device-access episode can be identified and evaluated under the study protocol.
• Sufficient procurement, scheduling, clinical, or administrative information is available to determine device-access timing and study outcomes.
• Participant falls within either the documented ICE catheter access-disruption cohort or the timely-access comparison cohort.
• Able to provide informed consent when prospective consent is required by the applicable IRB determination, or eligible for inclusion under an IRB-approved waiver or alteration of consent where applicable.

Exclusion Criteria:

• Younger than 18 years of age.
• No planned, requested, or clinically relevant intracardiac echocardiography catheter involvement in the associated cardiovascular procedure.
• Procurement or clinical records are insufficient to establish the timing or final disposition of the device-access episode.
• Device access occurred outside the predefined study observation period.
• Procedure delay or cancellation is clearly attributable solely to an unrelated clinical or administrative circumstance and no qualifying ICE catheter access event occurred.
• Participation would conflict with another protocol, institutional restriction, or applicable human-subject protection requirement.
• Individuals for whom required authorization, consent, or permitted IRB-approved waiver criteria are not satisfied.